All IBT Stories
Browse research highlights, faculty achievements, and trainee successes. Jump to a category below or scroll through every story.
A new AACR Cancer Discovery news feature on optogenetics’ reach into cancer cites Dr. Yubin Zhou’s light-controlled CAR T and related work at the Texas A&M Health Institute of Biosciences and Technology in Houston (including Nature Nanotechnology, 2021).
Read story →Research Highlights(3 stories)
Researchers at the Texas A&M Health Institute of Biosciences and Technology and the College of Veterinary Medicine & Biomedical Sciences found evidence that a chromosome 21 gene, SOD1, may drive an alternative hydrogen sulfide pathway linked to immune challenges in Down syndrome.
Read story →Dr. Yubin Zhou has received an NIGMS R35 award to study how cells control calcium signals at membrane contact sites—basic biology that underpins growth, stress response, and communication inside living cells.
Read story →Dr. Praveen Rajendran of IBT at Texas A&M University, in collaboration with Dr. Roderick Dashwood and Dr. Eduardo Vilar-Sanchez, will investigate low-dose drug combinations to prevent colitis-associated colorectal cancer.
Read story →Precision Medicine & Cancer Research(4 stories)
A new AACR Cancer Discovery news feature on optogenetics’ reach into cancer cites Dr. Yubin Zhou’s light-controlled CAR T and related work at the Texas A&M Health Institute of Biosciences and Technology in Houston (including Nature Nanotechnology, 2021).
Read story →A 2025 MedComm study from the Ramos laboratory at IBT, led by visiting scholar Dr. Abeer A.I. Hassanin, reported that exosomal LINE-1 mRNA profiles distinguished lung cancer from controls and reflected clinical features including stage, metastasis, and smoking history.
Read story →Dr. Yubin Zhou, director of the Center for Translational Cancer Research at IBT, discussed IBT-developed caffeine-activated genetic tools on the Heliox podcast, following coverage in the Journal of the American Chemical Society and Vital Record.
Read story →Dr. Sara Rogers leads pharmacogenomics implementation at Texas A&M Health, AI-enabled dementia-prevention research, and national personalized-medicine standards as chair of the U.S. Pharmacopeia Personalized Medicines Committee.
Read story →Faculty Spotlights(2 stories)
Dr. Thomas A. Kent, Welch Chair professor at IBT, has been named to the 2026 Texas Super Doctors list and reports Legacy Hall of Fame status for 15 consecutive years—clinical recognition for a physician-scientist rooted in research.
Read story →Dr. Kenneth S. Ramos, executive director of the Institute of Biosciences and Technology (IBT) at Texas A&M University and director of the Center for Genomic and Precision Medicine, has received the University's highest faculty honor.
Read story →Innovation & Drug Discovery(2 stories)
NVIDIA published a case study on Texas A&M’s VISION supercomputer highlighting Dr. Reid Powell’s IBT drug-discovery work: 10.4 million simulations in a week and more than 22,000 candidate molecules.
Read story →Led by Dr. Suzanne Tomlinson-Mathis, PhD, MBA, director of innovation and entrepreneurship at IBT, a Drug Discovery Today feature highlights Dr. Peter Davies, Dr. Clifford Stephan, and Dr. Margie Moczygemba and the IDDD Core Network, which has supported more than 750 projects and helped launch more than 60 startups.
Read story →Partnerships & Translational Impact(1 story)
In partnership with Wave Neuroscience, IBT investigators led a multisite clinical trial supporting FDA clearance of MeRT, the first personalized, biomarker-guided neuromodulation system cleared for post-traumatic stress disorder.
Read story →